- Stocks
- Pharma & Healthcare
- Genomic Valley
Genomic Valley share price
NSE: GVBLPharma & HealthcareBiotechnology
Genomic Valley at a glance
With a market capitalisation of ₹9 Cr, it ranks 3938th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was 9.1% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹0 Cr (−84.6% year on year) and net profit −₹0 Cr, on a standalone basis. Promoters held 46.06% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹9 CrRank 3938 on NSE
- Price to book
- 4.59×FY25
- EPS (TTM)
- ₹0.09to Q4 FY26
- ROE
- 9.1%FY25
- ROCE
- 11.3%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 42.2%FY25
- Book value / share
- ₹12.76FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Genomic Valley quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Revenue YoY | +166.7% | +200.0% | +450.0% | — | −43.8% | −57.1% | −77.3% | −84.6% |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr |
| Net profit YoY | +333.3% | +650.0% | +700.0% | — | −84.6% | −100.0% | −93.8% | — |
| Net margin | 81.3% | 71.4% | 72.7% | −30.8% | 22.2% | 0.0% | 20.0% | −25.0% |
| EPS | ₹0.42 | ₹0.48 | ₹0.51 | −₹0.27 | ₹0.08 | ₹0.01 | ₹0.03 | −₹0.03 |
Genomic Valley financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹0 Cr | ₹1 Cr |
| Operating profit | ₹0 Cr | −₹1 Cr | −₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹0 Cr | −₹1 Cr | −₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| EPS (₹) | ₹0.94 | −₹1.83 | −₹0.03 | ₹2.12 | ₹0.05 | ₹1.17 |
| Cash from operations | ₹0 Cr | ₹1 Cr | −₹2 Cr | −₹1 Cr | −₹0 Cr | ₹0 Cr |
| Total debt | ₹1 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
Genomic Valley shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.78% | 46.72% | 46.72% | 46.06% | 46.06% | 46.06% |
| Non-institutions | 53.22% | 53.28% | 53.28% | 53.94% | 53.94% | 53.94% |
Genomic Valley vs peers
The listed Pharma & Healthcare companies nearest to Genomic Valley by market capitalisation.
Ask anything about Genomic Valley
Pivot answers on the live chart with evidence you can check, and tests strategies against GVBL's own history. Try: “Why has GVBL moved over the last three months?” · “Backtest a 50-day moving-average crossover on GVBL over five years” · “Compare GVBL with LOOKS on margins and valuation”
Frequently asked questions about Genomic Valley
What is the market cap of Genomic Valley?
Genomic Valley's market capitalisation is ₹9 Cr (₹9 Cr) at the 22 Oct 2026 close, ranking 3938th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Genomic Valley?
Return on equity was 9.1% in FY25 and return on capital employed was 11.3% in FY25 (standalone figures).
Is Genomic Valley a debt-free company?
Genomic Valley is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Genomic Valley's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Genomic Valley reported revenue of ₹0 Cr, −84.6% year on year, and net profit of −₹0 Cr.
What is the shareholding pattern of Genomic Valley?
As of 30 Jun 2026: promoters 46.06%, non-institutions 53.94%.
Who are Genomic Valley's competitors?
The listed Pharma & Healthcare companies closest to Genomic Valley by market cap are Looks Health, Broach Lifecare, Clinitech Labor, Trinity League, Adline Chem Lab and Unjha Formula.
Is Genomic Valley a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Genomic Valley's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GVBL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text